{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:41:17Z","timestamp":1787622077173,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Vitiligo ist eine h\u00e4ufige, chronische Erkrankung, die zu einem Pigmentzellverlust der Haut f\u00fchrt. Obgleich es internationale Konsensusempfehlungen zur Diagnostik und Therapie sowie eine im April 2021 erschienene deutsche AWMF-S1-Leitlinie gibt, existieren keinerlei Daten zur Adh\u00e4renz dieser Richtlinien bei niedergelassenen deutschen Dermatologen. Ziel des vorliegenden Pilotprojektes war es, anhand einer Machbarkeitsstudie einen ersten Einblick in die routinem\u00e4\u00dfige Versorgungssituation von Menschen mit Vitiligo zu gewinnen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>In einer querschnittlichen Beobachtungsstudie haben wir 572 niedergelassene Dermatologen aus Deutschland mit einem Fragebogen adressiert und diese zu ihrer Einstellung zur Vitiligo, der leitlinienkonformen Diagnostik sowie den angebotenen erstattungsf\u00e4higen Therapieoptionen befragt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Mehrheitlich (53,7\u202f%) wurde Vitiligo als kosmetisches Problem betrachtet. \u00dcber die H\u00e4lfte (51,1\u202f%) der Haut\u00e4rzte wendete keine der abgefragten diagnostischen Methoden an, und rund ein Viertel (25,6\u202f%) nutzte keines der abgefragten Therapiemittel. Dermatologen, die Vitiligo als ernste Erkrankung betrachten, verwenden signifikant h\u00e4ufiger Diagnostikverfahren und verordnen signifikant h\u00e4ufiger leitliniengerechte Therapien als jene, die Vitiligo als kosmetisches Problem sehen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Unsere querschnittliche Beobachtungs- und Pilotstudie weist auf eine alarmierende Unterversorgung von Patienten mit dem Krankheitsbild einer Vitiligo im niedergelassenen Bereich hin. Weiterf\u00fchrende gro\u00dfe und detailliertere Studien in Deutschland sind n\u00f6tig, um unsere ersten Daten zu untermauern. Zus\u00e4tzlich braucht es Ma\u00dfnahmen, um eine leitliniengerechte Behandlung bei Vitiligo zu verbessern.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00105-026-05729-8","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:12:30Z","timestamp":1782925950000},"page":"524-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Versorgungssituation von Menschen mit Vitiligo","Medical care situation of people with vitiligo"],"prefix":"10.1007","volume":"77","author":[{"given":"Larissa","family":"Mientus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Steinbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"5729_CR1","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1468-3083.2009.03310.x","volume":"23","author":"KM Alghamdi","year":"2009","unstructured":"Alghamdi\u00a0KM (2009) A survey of vitiligo management among dermatologists in Saudi Arabia. J\u00a0Eur Acad Dermatol Venereol 23:1282\u20131288","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5729_CR2","first-page":"20","volume":"72","author":"M Augustin","year":"2024","unstructured":"Augustin\u00a0M, B\u00f6hm\u00a0M, Berneburg\u00a0M et\u00a0al (2024) Vitiligo: Krankheitslast erfordert medizinische Versorgung. Berufspolitik 72:20\u201325","journal-title":"Berufspolitik"},{"key":"5729_CR3","first-page":"365","volume":"20","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm\u00a0M, Schunter\u00a0JA, Fritz\u00a0K et\u00a0al (2022) S1-Leitlinie: Diagnostik und Therapie der Vitiligo. J\u00a0Dtsch Dermatol Ges 20:365\u2013379","journal-title":"J Dtsch Dermatol Ges"},{"key":"5729_CR4","first-page":"1327","volume":"22","author":"M B\u00f6hm","year":"2024","unstructured":"B\u00f6hm\u00a0M, Sommer\u00a0R, Gieler\u00a0U et\u00a0al (2024) Krankheit Vitiligo. Ein Positionspapier zur Stigmatisierung, Einschr\u00e4nkung der Lebensqualit\u00e4t und psychosozialen Komorbidit\u00e4t. J\u00a0Dtsch Dermatol Ges 22:1327\u20131335","journal-title":"J Dtsch Dermatol Ges"},{"key":"5729_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/ddg.15706_g","volume":"23","author":"M B\u00f6hm","year":"2025","unstructured":"B\u00f6hm\u00a0M, Tanew\u00a0A (2025) Vitiligo. J\u00a0Dtsch Dermatol Ges 23:968\u2013987","journal-title":"J Dtsch Dermatol Ges"},{"key":"5729_CR6","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.jaad.2019.06.022","volume":"81","author":"HC Chang","year":"2019","unstructured":"Chang\u00a0HC, Lin\u00a0MH, Huang\u00a0YC et\u00a0al (2019) The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J\u00a0Am Acad Dermatol 81:1442\u20131445","journal-title":"J Am Acad Dermatol"},{"key":"5729_CR7","first-page":"218","volume":"20","author":"KW Chuang","year":"2022","unstructured":"Chuang\u00a0KW, Chang\u00a0HC (2022) Association between vitiligo and metabolic syndrome: A systematic review and meta-analysis. J\u00a0Dtsch Dermatol Ges 20:218\u2013221","journal-title":"J Dtsch Dermatol Ges"},{"key":"5729_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/bjd\/ljae133","volume":"191","author":"V Eleftheriadou","year":"2024","unstructured":"Eleftheriadou\u00a0V, Delattre\u00a0C, Chetty-Mhlanga\u00a0S et\u00a0al (2024) Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. Br J Dermatol 191:216\u2013224","journal-title":"Br J Dermatol"},{"key":"5729_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine\u00a0K, Eleftheriadou\u00a0V, Jones\u00a0H et\u00a0al (2021) Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol 22:757\u2013774","journal-title":"Am J Clin Dermatol"},{"key":"5729_CR10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/jdv.19447","volume":"37","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine\u00a0K, Seneschal\u00a0J, Da Silva\u00a0A et\u00a0al (2023) Vitiligo patient population an disease burden in France: VIOLIN study results from CONSTANCES cohort. J\u00a0Eur Acad Dermatol Venereol 37:2249\u20132258","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5729_CR11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s13555-025-01412-3","volume":"15","author":"P Grimes","year":"2025","unstructured":"Grimes\u00a0P, Hamzavi\u00a0IH, Bibeau\u00a0K et\u00a0al (2025) Mental Health and Psychosocial Burden Among Patients with Skin of Color Living with Vitiligo: Findings from the Global VALIANT Study. Dermatol Ther (Heidelb) 15:1931\u20131939","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5729_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/bjd\/ljad245","volume":"189","author":"IH Hamzavi","year":"2023","unstructured":"Hamzavi\u00a0IH, Bibeau\u00a0K, Grimes\u00a0P et\u00a0al (2023) Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol 189:569\u2013577","journal-title":"Br J Dermatol"},{"key":"5729_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi\u00a0I, Jain\u00a0H, McLean\u00a0D et\u00a0al (2004) Parametric modeling of narrowband UV\u2011B phototherapy for vitiligo using a novel quantitative tool: The Vitiligo Area Scoring Index. Arch Dermatol 140:677\u2013683","journal-title":"Arch Dermatol"},{"key":"5729_CR14","unstructured":"https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/BAEK\/Ueber_uns\/Statistik\/2021\/2021_Statistik.pdf. Zugegriffen: 9. M\u00e4rz 2025"},{"key":"5729_CR15","unstructured":"https:\/\/www.hautnetz-deutschland.de\/events\/1-nationale-versorgungskonferenz-vitiligo-2026-hybrid\/ Zugegriffen 16. M\u00e4rz 2026"},{"key":"5729_CR16","unstructured":"https:\/\/www.who.int\/about\/governance\/constitution Zugegriffen: 12.\u00a0Januar 2025"},{"key":"5729_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","volume":"143","author":"JH Lee","year":"2023","unstructured":"Lee\u00a0JH, Ju\u00a0HJ, Seo\u00a0JM et\u00a0al (2023) Comorbidities in Patients with Vitiligo: A Systematic Review and Meta-Analysis. J\u00a0Invest Dermatol 143:777\u2013789.e6","journal-title":"J Invest Dermatol"},{"key":"5729_CR18","doi-asserted-by":"publisher","first-page":"e829","DOI":"10.1111\/jdv.18310","volume":"36","author":"VS Long","year":"2022","unstructured":"Long\u00a0VS, Law\u00a0YXT, Yew\u00a0YW, Choi\u00a0CE (2022) Risk of internal malignancies, cutaneous malignant melanoma and non-melanoma skin cancer among patients with vitiligo: a systematic review and meta-analysis. J\u00a0Eur Acad Dermatol Venereol 36:e829\u2013e831","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5729_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/CLEP.S304155","volume":"13","author":"N Mohr","year":"2021","unstructured":"Mohr\u00a0N, Petersen\u00a0J, Kirsten\u00a0N, Augustin\u00a0M (2021) Epidemiology of vitiligo - a dual population-based approach. Clin Epidemiol 13:373\u2013382","journal-title":"Clin Epidemiol"},{"key":"5729_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jid.2023.08.012","volume":"144","author":"A Rooker","year":"2024","unstructured":"Rooker\u00a0A, Ouwerkerk\u00a0W, Bekkenk\u00a0MW et\u00a0al (2024) The risk of keratinocyte cancer in Vitiligo and the potential mechanisms involved. J\u00a0Invest Dermatol 144:234\u2013242","journal-title":"J Invest Dermatol"},{"key":"5729_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin\u00a0D, Passeron\u00a0T, Pandya\u00a0AG et\u00a0al (2022) Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med 387:1445\u20131455","journal-title":"N Engl J Med"},{"key":"5729_CR22","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"P Seneschal","year":"2023","unstructured":"Seneschal\u00a0P, Speeckaert\u00a0R, Ta\u00efeb\u00a0A et\u00a0al (2023) Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations. J\u00a0Eur Acad Dermatol Venereol 37:2185\u20132195","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5729_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/bjd.20137","volume":"185","author":"J Shourick","year":"2021","unstructured":"Shourick\u00a0J, Ahmed\u00a0M, Seneschal\u00a0J et\u00a0al (2021) Development of a shared decision-making tool in vitiligo: an international study. Br J Dermatol 185:787\u2013796","journal-title":"Br J Dermatol"},{"key":"5729_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","volume":"20","author":"A Ta\u00efeb","year":"2007","unstructured":"Ta\u00efeb\u00a0A, Picardo\u00a0M et\u00a0al (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20:27\u201335","journal-title":"Pigment Cell Res"},{"key":"5729_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","volume":"136","author":"N van Geel","year":"2016","unstructured":"van Geel\u00a0N, Lommerts\u00a0J, Bekkenk\u00a0M et\u00a0al (2016) Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. J\u00a0Invest Dermatol 136:978\u2013984","journal-title":"J Invest Dermatol"},{"key":"5729_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2016.09.034","volume":"76","author":"N van Geel","year":"2017","unstructured":"van Geel\u00a0N, Lommerts\u00a0JE, Bekkenk\u00a0MW et\u00a0al (2017) Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). J\u00a0Am Acad Dermatol 76:464\u2013471","journal-title":"J Am Acad Dermatol"},{"key":"5729_CR27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel\u00a0N, Speeckaert\u00a0R, Ta\u00efeb\u00a0A et\u00a0al (2023) Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J\u00a0Eur Acad Dermatol Venereol 37:2173\u20132184","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05729-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:55Z","timestamp":1785769615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05729-8"}},"subtitle":["Eine Pilot- und Machbarkeitsstudie zum leitliniengerechten Management in deutschen Hautarztpraxen","A\u00a0pilot and feasibility study on guideline-oriented management in German dermatology practices"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5729"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05729-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0B\u00f6hm hat Beraterhonorare und\/oder Vortragshonorare von Pharmafirmen (AbbVie, Almirall, Boehringer, Incyte, Isispharma, Janssen-Cilag, MSD, Pfizer) erhalten, die Arzneimittel gegen Vitiligo entwickeln und vertreiben. R.\u00a0Sommer hat Beraterhonorare und\/oder Vortragshonorare von Pharmafirmen (AbbVie, Almirall, Incyte und Janssen-Cilag) erhalten, die Arzneimittel gegen Vitiligo entwickeln und vertreiben. M.\u00a0B\u00f6hm und R.\u00a0Sommer erhalten Forschungsgelder von Incyte zur Durchf\u00fchrung einer nichtinterventionellen Studie bei Menschen mit Vitiligo (VitiligoHealth). L.\u00a0Mientus und K.\u00a0Steinbrink geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Patienten wurden in dieser Studie nicht befragt. Alle an der Studie beteiligten Dermatologen erhielten ein Informationsschreiben und eine Einwilligungserkl\u00e4rung. Die R\u00fccksendung des ausgef\u00fcllten Fragebogens erfolgte in anonymer Form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}